Investors
Investors

Press Releases

DateSubject
December 21, 1999 Cerus Corporation Announces $25 Million Private Placement of Common Stock
December 9, 1999 Cerus Corporation Appoints C. Raymond Larkin, Jr. to Board of Directors
December 6, 1999 Cerus Reports Preclinical Study Results on Its Program In Allogeneic Bone Marrow Transplant
December 6, 1999 Cerus Presents Data On Pathogen Inactivation Systems For Blood Transfusion Products
November 4, 1999 Cerus Corporation Adopts Stockholder Rights Plan
October 26, 1999 Cerus Corporation Announces Third Quarter Results
October 26, 1999 Cerus Completes Successful Phase 1B Clinical Trial of its Red Blood Cell Pathogen Inactivation System Study Demonstrates Viability of Treated Red Blood Cells; No Immune Response Detected
October 5, 1999 Cerus Receives $800,000 NIH Grant for Allogeneic Bone Marrow Transplant Research
July 27, 1999 Cerus Corporation Announces Second Quarter Results
July 22, 1999 Cerus and Baxter Begin Enrollment in U.S. Phase 3 Trial of System to Improve the Safety of Platelet Transfusions
July 7, 1999 Cerus Corporation Appoints Vice President of Legal Affairs
June 30, 1999 Cerus Initiates Phase 1 Allogeneic Bone Marrow Transplant Study
May 12, 1999 Cerus Receives FDA Clearance to Proceed with Phase 3 Study of Its Fresh Frozen Plasma Pathogen Inactivation System
May 11, 1999 Cerus Initiates Transfusion In Phase 1b Clinical Trial Of Its Pathogen Inactivation System For Red Blood Cells
May 11, 1999 Cerus Initiates Transfusion in Phase 1B Clinical Trial Of Its Pathogen Inactivation System for Red Blood Cells
May 7, 1999 Cerus Corporation Appoints Chief Financial Officer
April 21, 1999 Cerus Corporation Announces First Quarter Results
March 31, 1999 Cerus Corporation Completes Stock Offering
March 4, 1999 Baxter Healthcare Purchase $9.5 Million of Cerus Corporation Convertible Preferred Stock
February 23, 1999 Cerus Receives FDA Clearance to Proceed With Clinical Trials Of Its System For Allogeneic Bone Marrow Transplantation
February 11, 1999 Cerus Corporation Announces Proposed Stock Offering
January 26, 1999 Cerus Corporation Announces Fourth Quarter and 1998 Results
January 26, 1999 Cerus Sets Preliminary Parameters For U.S. Phase 3 Platelet Trial
January 20, 1999 Cerus Corporation Announces New CFO and Promotions to Vice President for Commercialization